About this trial
The investigators' goal is to conduct a prospective multicenter study to evaluate the yield and outcomes of screening of pancreas cancer in individuals who are at-risk for pancreatic cancer. We plan to use International Cancer of the Pancreas Screening (CAPS3) Consortium recommendations to standardize study population, screening methodology, and study outcomes.
Eligibility criteria
Qualifiers
Inclusion criteria 1-3 are indications for pancreatic cancer screening as defined by the CAPS3 guidelines or updated national pancreatic cancer screening guidelines. Patients who do not meet these guidelines but are undergoing pancreatic cancer screening at the discretion of their treating physician at participating study centers will also be included in the study. Based upon the indication for screening, patients will be categorized as either meeting CAPS3 screening criteria, or not meeting CAPS3 screening criteria.
Familial Pancreatic cancer kindred. This is defined as family history of pancreas cancer that meet the criteria listed below.
If at least two affected relatives who are First degree relatives (FDR) to each other, of whom at least one is an FDR to the individual considered for surveillance
If at least three affected relatives on the same side of the family, of whom at least one is an FDR to the individual considered for surveillance
Disqualifiers
Patients presenting with symptoms suggestive of pancreatic cancer who are undergoing diagnostic EUS or MRCP e.g. acute recurrent pancreatitis, abnormal imaging
Trial design
Treatments tested in this trial
- Screening for pancreatic cancer
Treatment groups
Sponsors and collaborators
Beth Israel Deaconess Medical Center
Lead sponsor
Washington University School of Medicine
Collaborator
Zucker School of Medicine at Hofstra/Northwell
Collaborator
Rush University Medical Center
Collaborator
Wake Forest University
Collaborator
University of Arkansas
Collaborator